Oncology (Williston Park). 2018 Mar 15;32(3):98-101, 104.

Using Genomic Sequencing to Improve Management in Melanoma.

Oncology (Williston Park, N.Y.)

Pauline Funchain, Ahmad A Tarhini

PMID: 29548064

Abstract

Rapidly advancing genomic sequencing technologies are changing all areas of cancer, from diagnosis to surveillance, and prognostication to treatment. The role of genomic testing in melanoma is expanding, and multiple genomically based tests are available, including somatic tumor sequencing for actionable genetic alterations and tumor mutational burden, prognostic gene expression profiling from tumor tissue, and germline genetic testing from blood. The available testing options have varying levels of supporting data, from robust to preliminary. Here we summarize the available genomic and genetic tests for melanoma, and the level of evidence supporting each of these. We also discuss the current impact of genomic sequencing on the management of melanoma, as well as roles it may play in the near future.

Substances

• Circulating Tumor DNA
• BRAF protein, human
• Proto-Oncogene Proteins B-raf

MeSH terms

• Circulating Tumor DNA / analysis
• Genetic Testing
• Humans
• Melanoma / genetics
• Melanoma / secondary
• Melanoma / therapy
• Mutation
• Proto-Oncogene Proteins B-raf / genetics

Publication Types

• Journal Article